329 related articles for article (PubMed ID: 32984021)
1. Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: Study Protocol of a Randomized Controlled Trial.
Hu Y; Qin T; Li S; Zhang T; Xue J
Front Oncol; 2020; 10():1589. PubMed ID: 32984021
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
Hu Y; Zhou M; Tang J; Li S; Liu H; Hu J; Ma H; Liu J; Qin T; Yu X; Chen Y; Peng J; Zou Y; Zhang T; Xue J
Clin Cancer Res; 2023 Oct; 29(20):4088-4097. PubMed ID: 37556120
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
Yuan G; Cheng X; Li Q; Zang M; Huang W; Fan W; Wu T; Ruan J; Dai W; Yu W; Chen M; Guo Y; Hu X; Chen J
Onco Targets Ther; 2020; 13():12683-12693. PubMed ID: 33328740
[TBL] [Abstract][Full Text] [Related]
4. Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter propensity score-matching analysis.
Li Y; Guo J; Liu W; Pang H; Song Y; Wu S; Zhang F; Yan D; Chen J; An C; Li C
Hepatol Int; 2024 May; ():. PubMed ID: 38717693
[TBL] [Abstract][Full Text] [Related]
5. A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus.
Li X; Ding X; Liu M; Wang J; Sun W; Teng Y; Xu Y; Wu H; Li W; Zhou L; Chen J
Cancer Med; 2023 Aug; 12(16):16805-16814. PubMed ID: 37387602
[TBL] [Abstract][Full Text] [Related]
6. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
7. Apatinib Combined With Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
Fan W; Yuan G; Fan H; Li F; Wu Y; Zhao Y; Yao W; Wang Y; Xue M; Yang J; Li J
Clin Ther; 2019 Aug; 41(8):1463-1476. PubMed ID: 31303279
[TBL] [Abstract][Full Text] [Related]
8. Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma.
Zheng Y; Wang Z; Yan C; Yan M; Hou Z; Zheng R; Zhu Z; Li C
Ann Transl Med; 2020 Dec; 8(24):1684. PubMed ID: 33490196
[TBL] [Abstract][Full Text] [Related]
9. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
[TBL] [Abstract][Full Text] [Related]
10. Modified Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab for Advanced HCC: Two Case Reports.
Tian Y; Jin W; Sun H; Jin D; Kang D; Li Z; Piao L
J Hepatocell Carcinoma; 2023; 10():1587-1593. PubMed ID: 37791067
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of radiotherapy combined with lenvatinib plus PD-1 inhibitors as neo-adjuvant therapy in hepatocellular carcinoma with portal vein thrombus: protocol of an open-label, single-arm, prospective, multi-center phase I trial.
Li G; Shu B; Zheng Z; Yin H; Zhang C; Xiao Y; Yang Y; Yan Z; Zhang X; Yang S; Li G; Dong J
Front Oncol; 2022; 12():1051916. PubMed ID: 36505833
[TBL] [Abstract][Full Text] [Related]
12. Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center.
Ju S; Zhou C; Yang C; Wang C; Liu J; Wang Y; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
Front Oncol; 2021; 11():835889. PubMed ID: 35174073
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.
Xia Y; Tang W; Qian X; Li X; Cheng F; Wang K; Zhang F; Zhang C; Li D; Song J; Zhang H; Zhao J; Yao A; Wu X; Wu C; Ji G; Liu X; Zhu F; Qin L; Xiao X; Deng Z; Kong X; Li S; Yu Y; Xi W; Deng W; Qi C; Liu H; Pu L; Wang P; Wang X
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35379737
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study.
Zheng Z; Liu Z; Zhang H; Guo X; Jia X; Wang J; Meng L; Xin Y; Jiang X
Front Pharmacol; 2022; 13():894016. PubMed ID: 35656302
[No Abstract] [Full Text] [Related]
15. Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis.
Shui Y; Yu W; Ren X; Guo Y; Xu J; Ma T; Zhang B; Wu J; Li Q; Hu Q; Shen L; Bai X; Liang T; Wei Q
Radiat Oncol; 2018 Sep; 13(1):188. PubMed ID: 30253783
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis.
Choi BO; Choi IB; Jang HS; Kang YN; Jang JS; Bae SH; Yoon SK; Chai GY; Kang KM
BMC Cancer; 2008 Nov; 8():351. PubMed ID: 19038025
[TBL] [Abstract][Full Text] [Related]
17. Combination of Sorafenib, Camrelizumab, Transcatheter Arterial Chemoembolization, and Stereotactic Body Radiation Therapy as a Novel Downstaging Strategy in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Case Series Study.
Huang Y; Zhang Z; Liao W; Hu K; Wang Z
Front Oncol; 2021; 11():650394. PubMed ID: 34408974
[TBL] [Abstract][Full Text] [Related]
18. Study on Efficacy and Safety of Low-Dose Apatinib Combined with Camrelizumab and SOX Regimen as First-Line Treatment of Locally Advanced and Unresectable Gastric/Gastroesophageal Junction Cancer: A Protocol for an Open-Label, Dose Escalation and Extension Phase Ib Clinical Trial.
Wang KX; Cui TY; Yang XD; Wang GQ; Jiang QS; Sun H; Jiang NY; Yong XM; Shi CB; Ding YB; Chen XF; Fang YY
Onco Targets Ther; 2021; 14():4859-4865. PubMed ID: 34584426
[TBL] [Abstract][Full Text] [Related]
19. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus: a retrospective study.
Liu C; Xing W; Si T; Yu H; Guo Z
Oncotarget; 2017 Nov; 8(59):100734-100745. PubMed ID: 29246017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
